Prevalence of NAFLD in T2DM Patients

The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06445335

Acronym

PAD2ZOL

Enrollment

385

Registered

2024-06-06

Start date

2019-03-01

Completion date

2026-11-01

Last updated

2025-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver, Nonalcoholic, NAFLD, T2D, Type 2 Diabetes

Brief summary

To determine the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).

Interventions

DIAGNOSTIC_TESTFibroScan

Performance of a FibroScan measurement.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ≥ 18 years of age * Having type 2 diabetes mellitus (T2DM) * Written informed consent obtained

Exclusion criteria

* Excessive alcohol use * Exclusion of other causes of liver disease and secondary causes of steatosis

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients	Baseline	To determine the prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients followed at the department of Endocrinology in Ziekenhuis Oost-Limburg (ZOL), Genk, Belgium by means of FibroScan measurements.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026